Top Markets
#1 Status Status +24.09%
#2 Ontology Gas Ontology Gas +22.68%
#3 EXOD EXOD +22.08%
#4 ETHGas ETHGas +17.93%
#5 The Black Bull The Black Bull +15.99%
#6 Fake World Assets Fake World Assets +11.81%
#7 aelf aelf +10.18%
#8 Derive Derive +8.58%
#9 Gas Gas +8.36%
#10 Tornado Cash Tornado Cash +7.15%
Coin of the day
Status Status
設定
言語
日本
通貨
USD
テーマ
Promore Pharma AB (publ) Promore Pharma AB (publ)

Promore Pharma AB (publ)

PROMO
株式のランク #25506
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to... Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
株価
$1.34
最終同期: 2024-02-14
時価総額
$48.96M
変化（1日）
-12.94%
変化（1年）
0.00%
国
SE
取引 Promore Pharma AB (publ) (PROMO)

カテゴリー

Healthcare
Promore Pharma AB (publ)（PROMO）の収益
Aug 2026 時点の収益 TTM: 0
Promore Pharma AB (publ) の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Promore Pharma AB (publ) の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US